Direct Oral Anticoagulants

Phase 3Small molecule

Direct Oral Anticoagulants is one of 54 small molecule programs targeting Venous thrombosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThrombosisActive, not recruiting

Atrial FibrillationRecruiting

Venous ThrombosisPreclinical

Active, not recruiting

Atrial FibrillationPhase 3

Recruiting

Competition

Competitive Landscape

137 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Direct Oral Anticoagulants

Bayer

Phase 3

2 2

Calquence

AstraZeneca

Preclinical

1 3

Rituxan

Coumadin

3 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 9

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Complication

NCT05198960

Q1 2031

Post-ApprovalRecruiting

Atrial Fibrillation

NCT04700826

Clinical

Trials by Indication[1]

Atrial Fibrillation2 trials

Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT03596502·402,764 enrolled

Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation

Recruiting·UUniversity of Birmingham·Phase 4·NCT04700826·3,000 enrolled

Rivaroxaban1 trial

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

Completed· Bayer logo

Bayer··NCT04979780·3,708 enrolled

Venous thrombosis1 trial

DOAC in Unusual Site Venous Thrombosis

Completed·—··NCT03778502·358 enrolled

Pulmonary Embolism1 trial

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Unknown status·UUniversity of Birmingham·Phase 3·NCT04727437·1,466 enrolled

Complication1 trial

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting·UUniversity Hospital, Brest·Phase 3·NCT05198960·1,308 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Direct Oral Anticoagulants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Direct Oral Anticoagulants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Direct Oral Anticoagulants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Direct Oral Anticoagulants

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2031

Trials by Indication[1]

Atrial Fibrillation2 trials

Rivaroxaban1 trial

Venous thrombosis1 trial

Pulmonary Embolism1 trial

Complication1 trial

References

Drug Info

Quick Facts

Related News